Invariant NKT cells as a platform for CAR immunotherapy and prevention of acute Graft‐versus‐Host Disease
Authors:
Open Access
- 30 June 2019
- journal article
- editorial
- Published by Wiley in HemaSphere
- Vol. 3 (S2) , 31-34
Abstract
No abstract availableFunding Information
- Bloodwise
This publication has 32 references indexed in Scilit:
- Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survivalBlood, 2012
- The Diagnostic Value of CD1d Expression in a Large Cohort of Patients With B-Cell Chronic Lymphoproliferative DisordersAmerican Journal of Clinical Pathology, 2011
- Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4–dependent mechanismBlood, 2011
- Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft‐versus‐host disease in allogeneic bone marrow transplantationTransfusion, 2010
- Graft-versus-host diseaseThe Lancet, 2009
- Regulation of multiple myeloma survival and progression by CD1dBlood, 2009
- The Biology of NKT CellsAnnual Review of Immunology, 2007
- Distinct Functional Lineages of Human Vα24 Natural Killer T CellsJournal of Experimental Medicine, 2002
- Functionally Distinct Subsets of CD1d-restricted Natural Killer T Cells Revealed by CD1d Tetramer StainingJournal of Experimental Medicine, 2002
- An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells.Journal of Experimental Medicine, 1994